(304) Targeted mRNA delivery to metastatic tumors using functionalized nanoparticles

Introduction: Cancer immunotherapy faces challenges in treating metastases and solid tumors, particularly due to the lack of specific cell surface targets, which limits tumor eradication without harming healthy tissues1. Claudin 6 (CLDN6) has been identified as a potential target2, and the immune cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise as a cancer-specific therapy3. Here, we developed a lipid nanoparticle (LNP) platform functionalized with anti-CLDN6 antibodies to deliver TRAIL mRNA to colon cancer cells, aiming to enhance targeted treatment.